Wang Zhi-kuan, Meng Hai-yan, Han Chun, Yang Jun-lan
Department of Medical Oncology, PLA General Hospital, Beijing 100853, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Aug;32(4):403-6. doi: 10.3881/j.issn.1000-503X.2010.04.009.
To investigate the expressions of human epidermal growth factor receptor 2 (Her-2) and vascular endothelial growth factor (VEGF) in primary and recurrent metastatic breast cancers and explore their relationship.
The expressions of Her-2 and VEGF in 60 primary and recurrent metastatic breast cancers were detected using immunohistochemical methods. Their relationship was analyzed.
The positive rates of Her-2 and VEGF in the recurrent metastatic breast cancer were 40.00% and 53.33%, respectively, which were significantly higher than that in the primary breast cancer (18.33% and 31.67%) (P < 0.05). The total diversify rates of Her-2 and VEGF were 28.33% and 35.00%, respectively. Her-2 and VEGF expressions were significantly correlated between the primary and the recurrent metastatic breast cancers( P < 0.05).
Her-2 and VEGF may play synergic roles in the occurrence and development of breast cancer. Over-expressions of Her-2 and VEGF predict poor prognosis.
探讨人表皮生长因子受体2（Her-2）和血管内皮生长因子（VEGF）在原发性及复发性转移性乳腺癌中的表达情况，并探究它们之间的关系。
采用免疫组化方法检测60例原发性及复发性转移性乳腺癌中Her-2和VEGF的表达，并分析它们之间的关系。
复发性转移性乳腺癌中Her-2和VEGF的阳性率分别为40.00%和53.33%，显著高于原发性乳腺癌（18.33%和31.67%）（P<0.05）。Her-2和VEGF的总变化率分别为28.33%和35.00%。原发性与复发性转移性乳腺癌中Her-2和VEGF的表达显著相关（P<0.05）。
Her-2和VEGF可能在乳腺癌的发生发展中起协同作用。Her-2和VEGF的过表达预示预后不良。
